Clinical trials: Ischemia, Brain
Acute Ischemic Stroke
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
- Trial name
- SAIL (NCT07241520)
- Testing
- SHPL-49 Injection
- Where
- China
- Volunteers
- 1,096 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Acute Ischemic Stroke
Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke
Through the implementation of prospective, multi-center, randomized, parallel controlled clinical studies to verify the safety and effectiveness of Hongyuan thrombolysis device system in the intravascular treatment of acute…
- Trial name
- NCT05719688
- Testing
- Mechanical thrombectomy
- Where
- 18 sites in China
- Volunteers
- 202 people
- Sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTD
Heart Attack and Stroke
Emergency Call for Heart Attack and Stroke (ECHAS) - ECHAS One Study
ECHAS One will test the use of a smartphone app to assist patients to decide if it is necessary to call for emergency care with symptoms that could represent a heart attack or stroke.
- Trial name
- ECHAS (NCT05230069)
- Testing
- Interview
- Volunteers
- 200 people
- Sponsor
- Emergency Call for Heart Attack and Stroke (ECHAS)
Ischemic Stroke, Acute, Brain Diseases
Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke
- Conditions
- Ischemic Stroke, Acute, Brain Diseases, Cerebrovascular Disorders
- Trial name
- NCT04973332
- Testing
- Intracranial thrombectomy stent
- Where
- 14 sites in China
- Volunteers
- 218 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Cerebral Infarction
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral…
- Trial name
- NCT00234065
- Testing
- Cilostazol, Aspirin
- Where
- Japan
- Volunteers
- 2,800 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Acute Ischemic Stroke
Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke
The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease
- Trial name
- SPLENDID (NCT06386289)
- Testing
- Cereglide 92
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Ischemic Stroke, Post-stroke Cognitive Impairment
Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.
- Trial name
- NCT03202147
- Testing
- Cromolyn
- Sponsor
- AZTherapies, Inc.
Stroke
Study of ONO-2506 in Patients With Acute Ischemic Stroke
The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.
- Trial name
- NCT00229177
- Testing
- ONO-2506
- Where
- 9 sites in Japan
- Volunteers
- 757 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Stroke, Cerebral Ischemia
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00300196
- Testing
- Ancrod (Viprinex)
- Where
- 94 sites in United States, Australia and 9 more
- Volunteers
- 311 people
- Sponsor
- Neurobiological Technologies
Stroke, Ischemic, Stroke Hemorrhagic
Study on the Performance of a Machine Learning Algorithm Recognizing and Triaging Large Vessel Occlusions Using Non-contrast CT Scans
The goal of this prospective observational study is to assess the effectiveness and performance of Methinks AI stroke imaging software platform in acute Code Stroke patients, and as a comparator to study sites utilizing existing…
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Acute, Brain Ischemia
- Trial name
- SMART-LVO (NCT06216457)
- Testing
- AI software for Stroke
- Volunteers
- 5,000 people
- Sponsor
- Methinks Software SL
MCA - Middle Cerebral Artery Dissection
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Trial name
- NCT02953405
- Testing
- Clopidogrel
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Ischemic Stroke
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
- Trial name
- NCT03358901
- Testing
- YC-6, Vehicle
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Stroke
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
- Trial name
- WAVECREST2 (NCT03302494)
- Testing
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Where
- 25 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- Coherex Medical
Ischemic Stroke
Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study
Prospective, single-arm, open label, Safety and Performance clinical investigation.
- Trial name
- NCT02994563
- Testing
- Thrombectomy Device
- Where
- 4 sites in Spain, Sweden
- Volunteers
- 5 people
- Sponsor
- Amnis Therapeutics
Ischemic Stricture of Intestine
Safety and Effectiveness Evaluation of the ISS System in Treatment of Acute Ischemic Stroke
The primary objective of this pilot study is the assessment of the safety of the ISS500 System in patients who have experienced an acute ischemic stroke within the anterior circulation.
- Trial name
- ImpACT-1 (NCT03733236)
- Testing
- ISS Active Stimulation
- Where
- 2 sites in India
- Volunteers
- 98 people
- Sponsor
- BrainsGate
Stroke
Desmoteplase in Acute Ischemic Stroke (DIAS)
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after…
- Trial name
- NCT00638781
- Testing
- Desmoteplase
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- PAION Deutschland GmbH
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
The Influence of EMG-triggered Robotic Movement on Function and Mobility of Stroke Patients
Rehabilitation of lower limbs after a stroke supported by robots aims to return to independence and minimize disability caused by the incident, but the results have been mixed.
- Trial name
- NCT04497545
- Testing
- Luna EMG, lower limb rotor
- Where
- Poland
- Volunteers
- 71 people
- Sponsor
- EGZOTech